Navigation Links
Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
Date:3/31/2008

SHANGHAI, China, March 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, was very honored to have Professor David W. C. MacMillan, a renowned researcher from Princeton University, as a WuXi PharmaTech Science Seminar Series speaker who delivered a lecture to the company's young scientists on March 25, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Aiming to keep the company's young scientists abreast of the latest drug R&D knowledge and technologies, the WuXi PharmaTech Science Seminar Series is a monthly program that invites accomplished researchers from academia and the industry to share their wealth of experience and expertise with the company's scientists.

Dr. David MacMillan obtained his undergraduate degree from Glasgow University, and in 1990 moved to the University of California, Irvine, where he obtained his Ph.D. under the direction of Larry E. Overman. Following postdoctoral research with David A. Evans at Harvard University, Dr. MacMillan began his independent research career at the University of California, Berkeley, in 1998. In 2000, he joined the department of chemistry at Caltech, and was promoted to full professor in 2003. He was appointed to the A. Barton Hepbum Chair of Chemistry and Director of the Merck Center for Catalysis at Princeton University in June 2006.

Dr. MacMillan is a leader in the currently active area of asymmetric organocatalysis. His numerous accomplishments have found widespread industrial application and his success is evidenced by the numerous awards and honors he has received from professional associations like the Royal Society of Chemistry, the American Chemical Society and the industry.

"We are very honored and privileged to have Dr. MacMillan as one of our seminar speakers. His remarkable achievements in the field of organic synthesis will motivate our young scientists," said Dr. Shuhui Chen, Chief Scientific Officer of the company. "As a research-driven company serving global pharmaceutical, biotechnology and medical device companies, we believe science has no boundary. We will continue inviting heavy-weight speakers to WuXi so that our scientists can learn from the best, and ultimately provide better services to our customers."

About WuXi PharmaTech

WuXi PharmaTech, headquartered in Shanghai, China, is a leading global pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the U.S. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to pharmaceutical, biotechnology and medical device companies. Our services are designed to assist our global customers in shortening the time and lowering the cost of drug and medical device R&D by providing cost- effective and efficient outsourcing solutions. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton scientists break choleras lines of communication
2. First look: Princeton researchers peek into deepest recesses of human brain
3. Expert on Emerging Infectious Zoonotic Diseases Joining K-State as a Regents Distinguished Professor
4. University of Iowa professor identifies new eating disorder
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. George Mason University professor receives $2.6 million NIH grant to study Alzheimers disease
7. N.J. nurses are overworked according to Rutgers College of Nursing professor
8. Rutgers College of Nursing emerita professor Beverly Whipple receives FSSS book award
9. Boston University School of Medicine Professor receives award from American Heart Association
10. Louisiana Tech professor is Small Times Innovator of the Year
11. Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: